Murdoch Children's Research Institute, Victoria, Australia; Department of Neurology, Royal Children's Hospital, Victoria, Australia; Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Victoria, Australia; Department of Paediatrics, University of Melbourne, Victoria, Australia.
Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Eur J Med Genet. 2022 Sep;65(9):104551. doi: 10.1016/j.ejmg.2022.104551. Epub 2022 Jul 5.
Next generation sequencing studies have revealed an ever-increasing number of causes for genetic disorders of central nervous system white matter. A substantial number of disorders are identifiable from their specific pattern of biochemical and/or imaging findings for which single gene testing may be indicated. Beyond this group, the causes of genetic white matter disorders are unclear and a broader approach to genomic testing is recommended.
This study aimed to identify the genetic causes for a group of individuals with unclassified white matter disorders with suspected genetic aetiology and highlight the investigations required when the initial testing is non-diagnostic.
Twenty-six individuals from 22 families with unclassified white matter disorders underwent deep phenotyping and genome sequencing performed on trio, or larger, family groups. Functional studies and transcriptomics were used to resolve variants of uncertain significance with potential clinical relevance.
Causative or candidate variants were identified in 15/22 (68.2%) families. Six of the 15 implicated genes had been previously associated with white matter disease (COL4A1, NDUFV1, SLC17A5, TUBB4A, BOLA3, DARS2). Patients with variants in the latter two presented with an atypical phenotype. The other nine genes had not been specifically associated with white matter disease at the time of diagnosis and included genes associated with monogenic syndromes, developmental disorders, and developmental and epileptic encephalopathies (STAG2, LSS, FIG4, GLS, PMPCA, SPTBN1, AGO2, SCN2A, SCN8A). Consequently, only 46% of the diagnoses would have been made via a current leukodystrophy gene panel test.
These results confirm the importance of broad genomic testing for patients with white matter disorders. The high diagnostic yield reflects the integration of deep phenotyping, whole genome sequencing, trio analysis, functional studies, and transcriptomic analyses.
Genetic white matter disorders are genetically and phenotypically heterogeneous. Deep phenotyping together with a range of genomic technologies underpin the identification of causes of unclassified white matter disease. A molecular diagnosis is essential for prognostication, appropriate management, and accurate reproductive counseling.
下一代测序研究揭示了越来越多的中枢神经系统白质遗传疾病的病因。大量疾病可以根据其特定的生化和/或影像学发现模式来识别,这些疾病可能需要进行单基因检测。除此之外,遗传白质疾病的病因尚不清楚,建议采用更广泛的基因组检测方法。
本研究旨在确定一组具有疑似遗传病因的未分类白质疾病患者的遗传病因,并强调在初始检测无诊断结果时所需的进一步检查。
对 22 个家系的 26 名未分类白质疾病患者进行了深度表型分析和对三人或更大家系进行了基因组测序。利用功能研究和转录组学来解决具有潜在临床意义的不确定意义变异。
在 22 个家系中的 15 个(68.2%)家系中确定了致病或候选变异。在 15 个受影响的基因中,有 6 个(COL4A1、NDUFV1、SLC17A5、TUBB4A、BOLA3、DARS2)之前与白质疾病相关。在最后两个基因中有变异的患者表现出非典型表型。其他 9 个基因在诊断时尚未与白质疾病特异性相关,包括与单基因综合征、发育障碍和发育性癫痫性脑病相关的基因(STAG2、LSS、FIG4、GLS、PMPCA、SPTBN1、AGO2、SCN2A、SCN8A)。因此,目前的白质营养不良症基因检测只能诊断出 46%的病例。
这些结果证实了对白质疾病患者进行广泛基因组检测的重要性。高诊断率反映了深度表型分析、全基因组测序、三人分析、功能研究和转录组分析的综合应用。
遗传白质疾病在遗传和表型上具有异质性。深度表型分析与一系列基因组技术相结合,为未分类白质疾病的病因提供了依据。分子诊断对于预后、适当的管理和准确的生殖咨询至关重要。